The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from Business Wire

Illumina to Announce Fourth Quarter and Fiscal Year 2013 Financial Results on Tuesday, January 28, 2014

Wednesday, January 15, 2014

Illumina to Announce Fourth Quarter and Fiscal Year 2013 Financial Results on Tuesday, January 28, 2014

06:30 EST Wednesday, January 15, 2014

SAN DIEGO (Business Wire) -- Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for fourth quarter and fiscal year 2013 following the close of market on Tuesday, January 28, 2014.

On the same day, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) Jay Flatley, Chief Executive Officer; Marc Stapley, Senior Vice President and Chief Financial Officer; Francis deSouza, President; and Christian Henry, Senior Vice President and Chief Commercial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.

Conference Call Details

The conference call will begin at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) on Tuesday, January 28, 2014. Interested parties may listen to the call by dialing 888-713-4213 (passcode: 72154577), or if outside North America, by dialing +1-617-213-4865 (passcode: 72154577). Individuals may access the live teleconference in the Investor Relations section of Illumina's web site under the “Company” tab at www.illumina.com.

A replay of the conference call will be available from 6:00 p.m. Pacific Time (9:00 p.m. Eastern Time) on January 28, 2014 through February 4, 2014 by dialing 888-286-8010 (passcode: 88834345), or if outside North America, by dialing +1-617-801-6888 (passcode: 88834345).

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.

Illumina, Inc.
Investors:
Rebecca Chambers, 858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple, 858-882-6822
pr@illumina.com

Products
  • Globe Unlimited

    Digital all access pass across devices. subscribe

  • The Globe and Mail Newspaper

    Newspaper delivered to your doorstep. subscribe

  • Globe2Go

    The digital replica of our newspaper. subscribe

  • Globe eBooks

    A collection of articles by the Globe. subscribe

See all Globe Products

Advertise with us

GlobeLink.ca

Your number one partner for reaching Canada's Influential Achievers. learn more

The Globe at your Workplace
Our Company
Customer Service
Globe Recognition
Mobile Apps
NEWS APP
INVESTING APP
Other Sections